Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dose-comparison study of telitacicept in relapsing-remitting multiple sclerosis
CTR20202427Phase 2Terminated
- Sponsor
- RemeGen
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in multiple sclerosis (MS), sponsored by RemeGen. Started Jun 2021; status: terminated.
02
Drugs
telitacicept
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20202427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202427.